A Phase 1/2 randomized, placebo-controlled study evaluating the safety, tolerability and efficacy of AKCEA-ANGPTL3-LRx designed to lower ANGPTL3 levels
Phase of Trial: Phase I/II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs IONIS ANGPTL3 LRx (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions
- 01 Jun 2017 New trial record
- 25 May 2017 Results from this trial have been published in The New England Journal of Medicine, according to an Akcea Therapeutics media release.
- 25 May 2017 Results published in an Akcea Therapeutics media release.